Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients

Not yet recruitingOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
AmputationOsseointegration
Interventions
DRUG

5-aminolevulinic acid (5-ALA)

All patients who are recruited and enrolled into this study use topical 5- ALA, in combination with the light delivery device as part of their standard stoma management.

DEVICE

Photodynamic therapy (PDT)

All patients who are recruited and enrolled into this study use topical 5- ALA, in combination with the light delivery device photodynamic therapy device as part of their standard stoma management.

All Listed Sponsors
collaborator

Walter Reed Army Medical Center

FED

lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT06777511 - Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients | Biotech Hunter | Biotech Hunter